Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial

James Larkin; Richard Marais; Nuria Porta; David Gonzalez de Castro; Lisa Parsons; Christina Messiou; Gordon Stamp; Lisa Thompson; Kim Edmonds; Sarah Sarker; Jane Banerji; Paul Lorigan; Thomas R Jeffry Evans; Pippa Corrie; Ernest Marshall; Mark R Middleton; Paul Nathan; Steve Nicholson; Christian Ottensmeier; Ruth Plummer; Judith Bliss; Sara Valpione; Samra Turajlic

doi:10.1016/j.xcrm.2024.101435

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial

James Larkin, Richard Marais, Nuria Porta, David Gonzalez de Castro, Lisa Parsons, Christina Messiou, Gordon Stamp, Lisa Thompson, Kim Edmonds, Sarah Sarker, Jane Banerji, Paul Lorigan, Thomas R Jeffry Evans, Pippa Corrie, Ernest Marshall, Mark R Middleton, Paul Nathan, Steve Nicholson, Christian Ottensmeier, Ruth PlummerJudith Bliss, Sara Valpione, Samra Turajlic

Research output: Contribution to journal › Article › peer-review

Abstract

Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM. KIT mutations are identified in 39/219 screened patients (18%); of 29/39 treated, 26 are evaluable for primary analysis. Six patients were alive and progression free at 6 months (local radiology review, 25%); 5/26 (19%) had objective response at 12 weeks; median OS was 7.7 months; ddPCR assay correctly identifies KIT alterations in circulating tumor DNA (ctDNA) in 16/17 patients. Nilotinib is active in KIT-mutant AM and MM, comparable to other KIT inhibitors, with demonstrable activity in nonhotspot KIT mutations, supporting broadening of KIT evaluation in AM and MM. Our results endorse further investigations of nilotinib for the treatment of KIT-mutated melanoma. This clinical trial was registered with ISRCTN (ISRCTN39058880) and EudraCT (2009-012945-49).

Original language	English
Article number	101435
Journal	Cell reports. Medicine
Volume	5
Issue number	3
Early online date	27 Feb 2024
DOIs	https://doi.org/10.1016/j.xcrm.2024.101435
Publication status	Published - 19 Mar 2024

Keywords

KIT mutation
acral
liquid biopsy
melanoma
mucosal
tyrosine kinase inhibitor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.xcrm.2024.101435Licence: CC BY

Cite this

Larkin, J., Marais, R., Porta, N., Gonzalez de Castro, D., Parsons, L., Messiou, C., Stamp, G., Thompson, L., Edmonds, K., Sarker, S., Banerji, J., Lorigan, P., Evans, T. R. J., Corrie, P., Marshall, E., Middleton, M. R., Nathan, P., Nicholson, S., Ottensmeier, C., ... Turajlic, S. (2024). Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial. Cell reports. Medicine, 5(3), Article 101435. https://doi.org/10.1016/j.xcrm.2024.101435

@article{22dbe6484eba4ffcb0ca468bee4f260a,

title = "Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial",

abstract = "Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM. KIT mutations are identified in 39/219 screened patients (18%); of 29/39 treated, 26 are evaluable for primary analysis. Six patients were alive and progression free at 6 months (local radiology review, 25%); 5/26 (19%) had objective response at 12 weeks; median OS was 7.7 months; ddPCR assay correctly identifies KIT alterations in circulating tumor DNA (ctDNA) in 16/17 patients. Nilotinib is active in KIT-mutant AM and MM, comparable to other KIT inhibitors, with demonstrable activity in nonhotspot KIT mutations, supporting broadening of KIT evaluation in AM and MM. Our results endorse further investigations of nilotinib for the treatment of KIT-mutated melanoma. This clinical trial was registered with ISRCTN (ISRCTN39058880) and EudraCT (2009-012945-49).",

keywords = "KIT mutation, acral, liquid biopsy, melanoma, mucosal, tyrosine kinase inhibitor",

author = "James Larkin and Richard Marais and Nuria Porta and {Gonzalez de Castro}, David and Lisa Parsons and Christina Messiou and Gordon Stamp and Lisa Thompson and Kim Edmonds and Sarah Sarker and Jane Banerji and Paul Lorigan and Evans, {Thomas R Jeffry} and Pippa Corrie and Ernest Marshall and Middleton, {Mark R} and Paul Nathan and Steve Nicholson and Christian Ottensmeier and Ruth Plummer and Judith Bliss and Sara Valpione and Samra Turajlic",

year = "2024",

month = mar,

day = "19",

doi = "10.1016/j.xcrm.2024.101435",

language = "English",

volume = "5",

journal = "Cell reports. Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "3",

}

Larkin, J, Marais, R, Porta, N, Gonzalez de Castro, D, Parsons, L, Messiou, C, Stamp, G, Thompson, L, Edmonds, K, Sarker, S, Banerji, J, Lorigan, P, Evans, TRJ, Corrie, P, Marshall, E, Middleton, MR, Nathan, P, Nicholson, S, Ottensmeier, C, Plummer, R, Bliss, J, Valpione, S & Turajlic, S 2024, 'Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial', Cell reports. Medicine, vol. 5, no. 3, 101435. https://doi.org/10.1016/j.xcrm.2024.101435

TY - JOUR

T1 - Nilotinib in KIT-driven advanced melanoma

T2 - Results from the phase II single-arm NICAM trial

AU - Larkin, James

AU - Marais, Richard

AU - Porta, Nuria

AU - Gonzalez de Castro, David

AU - Parsons, Lisa

AU - Messiou, Christina

AU - Stamp, Gordon

AU - Thompson, Lisa

AU - Edmonds, Kim

AU - Sarker, Sarah

AU - Banerji, Jane

AU - Lorigan, Paul

AU - Evans, Thomas R Jeffry

AU - Corrie, Pippa

AU - Marshall, Ernest

AU - Middleton, Mark R

AU - Nathan, Paul

AU - Nicholson, Steve

AU - Ottensmeier, Christian

AU - Plummer, Ruth

AU - Bliss, Judith

AU - Valpione, Sara

AU - Turajlic, Samra

PY - 2024/3/19

Y1 - 2024/3/19

N2 - Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM. KIT mutations are identified in 39/219 screened patients (18%); of 29/39 treated, 26 are evaluable for primary analysis. Six patients were alive and progression free at 6 months (local radiology review, 25%); 5/26 (19%) had objective response at 12 weeks; median OS was 7.7 months; ddPCR assay correctly identifies KIT alterations in circulating tumor DNA (ctDNA) in 16/17 patients. Nilotinib is active in KIT-mutant AM and MM, comparable to other KIT inhibitors, with demonstrable activity in nonhotspot KIT mutations, supporting broadening of KIT evaluation in AM and MM. Our results endorse further investigations of nilotinib for the treatment of KIT-mutated melanoma. This clinical trial was registered with ISRCTN (ISRCTN39058880) and EudraCT (2009-012945-49).

AB - Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM. KIT mutations are identified in 39/219 screened patients (18%); of 29/39 treated, 26 are evaluable for primary analysis. Six patients were alive and progression free at 6 months (local radiology review, 25%); 5/26 (19%) had objective response at 12 weeks; median OS was 7.7 months; ddPCR assay correctly identifies KIT alterations in circulating tumor DNA (ctDNA) in 16/17 patients. Nilotinib is active in KIT-mutant AM and MM, comparable to other KIT inhibitors, with demonstrable activity in nonhotspot KIT mutations, supporting broadening of KIT evaluation in AM and MM. Our results endorse further investigations of nilotinib for the treatment of KIT-mutated melanoma. This clinical trial was registered with ISRCTN (ISRCTN39058880) and EudraCT (2009-012945-49).

KW - KIT mutation

KW - acral

KW - liquid biopsy

KW - melanoma

KW - mucosal

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85187660035&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2024.101435

DO - 10.1016/j.xcrm.2024.101435

M3 - Article

C2 - 38417447

SN - 2666-3791

VL - 5

JO - Cell reports. Medicine

JF - Cell reports. Medicine

IS - 3

M1 - 101435

ER -

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this